6/19/2019 1:15:19 PM
Wedbush Reiterates Biomarin Pharmaceutical Inc. (BMRN) At Outperform With $128 Price Target
6/18/2019 8:33:15 AM
BioMarin : Vosoritide Phase 2 Study Shows Sustained Annualized Growth Up To 42 Months In Children With Achondroplasia
6/4/2019 8:32:22 AM
BioMarin Announces Approval Of Vimizim In China For Treatment Of Morquio A Syndrome
5/28/2019 7:00:12 AM
BioMarin'Phase3 Cohort Of Valoctocogene Roxaparvovec,Gene Therapy Study In Severe Hemophilia A Met PreSpecified Criteria
5/28/2019 6:53:15 AM
BioMarin Provides 3 Years Of Data From Phase1/2 Study Of Valoctocogene Roxaparvovec Gene Therapy For Severe Hemophilia A
5/6/2019 10:15:36 AM
BioMarin Pharma : EU Approves Palynziq For Treatment Of Phenylketonuria In Patients Aged 16 Years Or Older
4/25/2019 4:08:32 PM
BioMarin Q1 Loss/share $0.32 Vs. Loss $0.26 Year Ago
3/1/2019 7:32:46 AM
BioMarin Receives Positive CHMP Opinion In Europe For Palynziq
2/26/2019 7:55:17 AM
Wedbush Is Cutting Biomarin Pharmaceutical Inc. (BMRN) FY20 Rev. Estimate To 1940 M From 2002 M
2/26/2019 7:55:05 AM
Wedbush Is Lowering Biomarin Pharmaceutical Inc. (BMRN) Q4 20 Rev. Estimate To 519.1 M From 528.3 M
2/26/2019 7:54:52 AM
Wedbush Is Lowering Biomarin Pharmaceutical Inc. (BMRN) Q3 20 Rev. Estimate To 496.0 M From 508.2 M
2/26/2019 7:54:37 AM
Wedbush Is Cutting Biomarin Pharmaceutical Inc. (BMRN) Q2 20 Rev. Estimate To 472.6 M From 495.4 M
2/26/2019 7:54:22 AM
Wedbush Is Cutting Biomarin Pharmaceutical Inc. (BMRN) Q1 20 Rev. Estimate To 452.4 M From 470.2 M
2/26/2019 7:53:45 AM
Wedbush Is Cutting Biomarin Pharmaceutical Inc. (BMRN) FY19 Rev. Estimate To 1682 M From 1738 M